In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

Detalles Bibliográficos
Autores principales: Osanto, Susanne, Woei-A-Jin, F J Sherida H, Coenraad, Minneke J, Weijl, Nir I, Burgmans, Mark C, Burggraaf, Jacobus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732251/
https://www.ncbi.nlm.nih.gov/pubmed/36269167
http://dx.doi.org/10.1093/oncolo/oyac215
_version_ 1784846085908332544
author Osanto, Susanne
Woei-A-Jin, F J Sherida H
Coenraad, Minneke J
Weijl, Nir I
Burgmans, Mark C
Burggraaf, Jacobus
author_facet Osanto, Susanne
Woei-A-Jin, F J Sherida H
Coenraad, Minneke J
Weijl, Nir I
Burgmans, Mark C
Burggraaf, Jacobus
author_sort Osanto, Susanne
collection PubMed
description This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.
format Online
Article
Text
id pubmed-9732251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97322512022-12-13 In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma Osanto, Susanne Woei-A-Jin, F J Sherida H Coenraad, Minneke J Weijl, Nir I Burgmans, Mark C Burggraaf, Jacobus Oncologist Letter to the Editor This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma. Oxford University Press 2022-10-21 /pmc/articles/PMC9732251/ /pubmed/36269167 http://dx.doi.org/10.1093/oncolo/oyac215 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Letter to the Editor
Osanto, Susanne
Woei-A-Jin, F J Sherida H
Coenraad, Minneke J
Weijl, Nir I
Burgmans, Mark C
Burggraaf, Jacobus
In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
title In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
title_full In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
title_fullStr In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
title_full_unstemmed In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
title_short In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
title_sort in reply: neoadjuvant tki study in early- and intermediate stage hepatocellular carcinoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732251/
https://www.ncbi.nlm.nih.gov/pubmed/36269167
http://dx.doi.org/10.1093/oncolo/oyac215
work_keys_str_mv AT osantosusanne inreplyneoadjuvanttkistudyinearlyandintermediatestagehepatocellularcarcinoma
AT woeiajinfjsheridah inreplyneoadjuvanttkistudyinearlyandintermediatestagehepatocellularcarcinoma
AT coenraadminnekej inreplyneoadjuvanttkistudyinearlyandintermediatestagehepatocellularcarcinoma
AT weijlniri inreplyneoadjuvanttkistudyinearlyandintermediatestagehepatocellularcarcinoma
AT burgmansmarkc inreplyneoadjuvanttkistudyinearlyandintermediatestagehepatocellularcarcinoma
AT burggraafjacobus inreplyneoadjuvanttkistudyinearlyandintermediatestagehepatocellularcarcinoma

Ejemplares similares